Developing a molecular level understanding of photodynamic therapy using femtosecond pump-probe spectroscopy

使用飞秒泵浦探针光谱学对光动力疗法进行分子水平的理解

• 批准号: G0902229/1
• 负责人: Helen Fielding
• 金额: $ 10.77万
• 依托单位: University College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2011
• 资助国家: 英国
• 起止时间: 2011 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0902229%2F1
• 关键词: Developing; molecular; level; understanding; photodynamic

Photodynamic therapy (PDT) uses light-activated drugs to treat diseases ranging from cancer to age-related macular degeneration and bacterial infections. It is based on the concept that a non-toxic chemical, referred to as a photosensitiser, is localised preferentially in the target site and is then activated by light, usually delivered by fibre-optics, so that there is minimal damage to surrounding healthy tissue. The absorption of light triggers a sequence of photophysical and photochemical processes that generate reactive oxygen species which destroy cancer cells, neovasculature or bacteria.The choice of photosensitiser, the drug-light time interval, drug dose and light flux can be treated as adjustable parameters, to be optimised for a particular PDT. The objective of this proposal is to develop a detailed understanding of the fundamental photophysics, photochemistry and photobiology of PDT at the molecular level. Such understanding is essential if we are to develop the capability to design efficient photosensitisers for specific treatments from first principles.

光动力疗法（PDT）使用光激活药物治疗从癌症到年龄相关性黄斑变性和细菌感染的疾病。它是基于这样的概念，即一种无毒的化学物质，被称为光敏剂，优先定位在目标部位，然后被光激活，通常由光纤传递，因此对周围健康组织的损害最小。光的吸收触发一系列生物物理和光化学过程，产生活性氧，破坏癌细胞，新生血管或细菌。光敏剂的选择，药物-光的时间间隔，药物剂量和光通量可以被视为可调参数，以优化特定的PDT。本计划的目标是在分子水平上对PDT的基本物理学、光化学和光生物学有详细的了解。如果我们要发展从第一原理设计用于特定治疗的有效光敏剂的能力，这种理解是必不可少的。